Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
$0.33
$0.34
$0.00
▼
$2.85
$13.46M-1.8232,226 shs100 shs
Equillium, Inc. stock logo
EQ
Equillium
$2.42
+2.5%		$2.57
$0.76
▼
$3.54
$153.13M1.82618,992 shs60,200 shs
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$0.20
+0.9%		$0.40
$0.18
▼
$2.14
$2.91M1.762.15 million shs68,862 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
▼
$2.14
$7.94M0.688.94 million shsN/A
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
0.00%-5.69%0.00%-20.63%-88.15%
Equillium, Inc. stock logo
EQ
Equillium
+8.26%+1.29%-4.07%-16.90%+21.03%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
-0.46%-18.51%-40.84%-75.28%-90.65%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%0.00%0.00%+100.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
$0.33
$0.34
$0.00
▼
$2.85
$13.46M-1.8232,226 shs100 shs
Equillium, Inc. stock logo
EQ
Equillium
$2.42
+2.5%		$2.57
$0.76
▼
$3.54
$153.13M1.82618,992 shs60,200 shs
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$0.20
+0.9%		$0.40
$0.18
▼
$2.14
$2.91M1.762.15 million shs68,862 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
▼
$2.14
$7.94M0.688.94 million shsN/A
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
0.00%-5.69%0.00%-20.63%-88.15%
Equillium, Inc. stock logo
EQ
Equillium
+8.26%+1.29%-4.07%-16.90%+21.03%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
-0.46%-18.51%-40.84%-75.28%-90.65%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%0.00%0.00%+100.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
1.00
SellN/AN/A
Equillium, Inc. stock logo
EQ
Equillium
2.91
Moderate Buy$7.57212.87% Upside
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
0.00
N/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ANEB, MTNB, EQ, and OBSV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2026
Equillium, Inc. stock logo
EQ
Equillium
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
7/21/2026
Equillium, Inc. stock logo
EQ
Equillium
Clear Str Llc logo
Clear Str
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/13/2026
Equillium, Inc. stock logo
EQ
Equillium
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight
7/13/2026
Equillium, Inc. stock logo
EQ
Equillium
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
6/24/2026
Equillium, Inc. stock logo
EQ
Equillium
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
5/28/2026
Equillium, Inc. stock logo
EQ
Equillium
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingStrong-Buy$7.00
5/28/2026
Equillium, Inc. stock logo
EQ
Equillium
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$5.00
5/28/2026
Equillium, Inc. stock logo
EQ
Equillium
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$12.00
5/28/2026
Equillium, Inc. stock logo
EQ
Equillium
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$1.00 ➝ $6.00
(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/A$0.28 per shareN/A
Equillium, Inc. stock logo
EQ
Equillium
N/AN/AN/AN/A$0.88 per shareN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$1.10M2.65N/AN/A$0.12 per share1.65
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A$0.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$8.48M-$0.19N/AN/AN/AN/A-74.57%-68.96%9/23/2026 (Estimated)
Equillium, Inc. stock logo
EQ
Equillium
-$22.40M-$0.20N/AN/AN/AN/A-41.15%-38.29%11/12/2026 (Estimated)
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
-$10.35M-$3.89N/AN/AN/AN/A-166.11%-102.20%N/A
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/A

Latest ANEB, MTNB, EQ, and OBSV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/23/2026Q4 2026
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$0.10N/AN/AN/AN/AN/A
8/13/2026Q2 2026
Equillium, Inc. stock logo
EQ
Equillium
-$0.0540-$0.04+$0.0140-$0.04N/AN/A
8/13/2026Q2 2026
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/A-$0.21N/A-$0.21N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/AN/A
Equillium, Inc. stock logo
EQ
Equillium
N/AN/AN/AN/AN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/A
6.24
6.24
Equillium, Inc. stock logo
EQ
Equillium
N/A
23.40
23.40
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/A
0.85
0.85
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61

Institutional Ownership

CompanyInstitutional Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
28.40%
Equillium, Inc. stock logo
EQ
Equillium
27.05%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
11.77%
ObsEva SA stock logo
OBSV
ObsEva
17.52%

Insider Ownership

CompanyInsider Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
80.60%
Equillium, Inc. stock logo
EQ
Equillium
17.84%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
4.60%
ObsEva SA stock logo
OBSV
ObsEva
14.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
440.79 million7.91 millionNot Optionable
Equillium, Inc. stock logo
EQ
Equillium
4063.41 million52.10 millionNot Optionable
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
3014.69 million14.02 millionN/A
ObsEva SA stock logo
OBSV
ObsEva
5077.97 million66.74 millionNot Optionable

Recent News About These Companies

ObsEva files uterine fibroid drug in US, chasing AbbVie, Myovant
August 31, 2024  |  pharmaphorum.comP
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin
April 3, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/04/03/2856586/0/en/obseva-announces-delisting-from-six-swiss-exchange-and-exemption-from-certain-obligations-associated-with-the-maintenance-of-listin.html
ObsEva Announces Update on Board of Directors
March 19, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/03/19/2848274/0/en/obseva-announces-update-on-board-of-directors.html
ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023
February 28, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/02/28/2836594/0/en/obseva-announces-wind-down-of-operations-and-notifies-six-that-it-will-lack-the-resources-to-establish-audited-ifrs-financial-statements-for-2023.html
ObsEva SA OBSN
November 11, 2023  |  morningstar.comM
ObsEva SA OBSEF
November 11, 2023  |  morningstar.comM
ObsEva (NASDAQ: OBSV)
June 18, 2023  |  fool.comhttps://www.fool.com/quote/nasdaq/obsv/
Tocolytic Agents Market to a Steady Revenue CAGR of 5.3% by ... - InvestorsObserver
May 10, 2023  |  news.google.comN
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - Yahoo Finance
May 2, 2023  |  news.google.comN
ObsEva Says Fabien De Ladonchamps Is New CEO - Nasdaq
May 2, 2023  |  news.google.comN
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - GlobeNewswire
May 2, 2023  |  news.google.comN
Gameto Appoints Teri Loxam as Chief Financial Officer - citybiz
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - Marketscreener.com
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - Yahoo Finance
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - Benzinga
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - EIN News
April 28, 2023  |  news.google.comN
Gameto Expands Executive Team with the Addition of Teri Loxam as ... - PR Newswire
April 28, 2023  |  news.google.comN
Endometriosis Market to Hit USD 3.9 Bn by 2029: Competitive ... - Digital Journal
April 26, 2023  |  news.google.comN
Endometriosis Pain Pipeline Insight, Emerging Therapies, Key Players, and Clinical Stages - openPR
April 23, 2023  |  news.google.comN
ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq - Marketscreener.com
April 21, 2023  |  news.google.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
Electrical substation with transmission towers and power lines in the foreground, with a city skyline at sunset in the background.
3 Dividend Champion Utilities for a Market That Can't Sit Still
By Dan Schmidt | August 10, 2026
Digital display of multiple financial charts, including line, candlestick, bar, heat map, and scatter plot graphs.
3 Unexpected ETFs Crushing the Market This Summer
By Nathan Reiff | August 16, 2026
Rendering of an electric vertical takeoff aircraft (eVTOL) on a rooftop landing pad above a city skyline.
Cleared for Takeoff: Archer Aviation Changes the Math on eVTOL
By Jeffrey Neal Johnson | August 13, 2026
A stylized computer chip labeled ETF surrounded by glowing circuit board lines and digital blocks.
Why These 3 Equal Weight ETFs Have Outperformed the S&P This Year
By Nathan Reiff | August 8, 2026
Anebulo Pharmaceuticals stock logo

Anebulo Pharmaceuticals NASDAQ:ANEB

$0.33 0.00 (0.00%)
As of 08/26/2026 09:30 AM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Equillium stock logo

Equillium NASDAQ:EQ

$2.42 +0.06 (+2.54%)
As of 09:56 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Matinas Biopharma stock logo

Matinas Biopharma NYSEAMERICAN:MTNB

$0.20 +0.00 (+0.87%)
As of 09:33 AM Eastern

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

ObsEva stock logo

ObsEva NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas